Spruce Biosciences (SPRB) Other Non-Current Assets (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Other Non-Current Assets of $539000.0 for Q1 2026, up 164.22% year-over-year from $204000.0 in Q1 2025, and up 121.81% quarter-over-quarter from $243000.0 in Q4 2025.
Spruce Biosciences (SPRB) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Other Non-Current Assets for 8 consecutive years, with $539000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 164.22% year-over-year to $539000.0; the TTM figure through Mar 2026 stood at $539000.0 (up 164.22% YoY), while the FY2025 annual figure was $243000.0, up 252.17% from the prior year.
- Other Non-Current Assets rose to $539000.0 in Q1 2026 per SPRB's latest filing, from $243000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $678000.0 in Q1 2022 and bottomed at $62000.0 in Q3 2025.
- Historically, Other Non-Current Assets has averaged $427235.3 across 5 years, with a median of $536000.0 in 2023.
- On a YoY basis, Other Non-Current Assets climbed as much as 252.17% in 2025 and fell as far as 88.32% in 2025.
- Spruce Biosciences' Other Non-Current Assets stood at $640000.0 in 2022, then retreated by 9.06% to $582000.0 in 2023, then tumbled by 88.14% to $69000.0 in 2024, then surged by 252.17% to $243000.0 in 2025, then soared by 121.81% to $539000.0 in 2026.
- Business Quant data shows SPRB's Other Non-Current Assets at $539000.0 in Q1 2026, $243000.0 in Q4 2025, and $62000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | 539,000.00 |
| Dec 31, 2025 | 243,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 64,000.00 |
| Mar 31, 2025 | 204,000.00 |
| Dec 31, 2024 | 69,000.00 |
| Sep 30, 2024 | 531,000.00 |
| Jun 30, 2024 | 547,000.00 |
| Mar 31, 2024 | 553,000.00 |
| Dec 31, 2023 | 582,000.00 |
| Sep 30, 2023 | 607,000.00 |
| Jun 30, 2023 | 536,000.00 |
| Mar 31, 2023 | 525,000.00 |
| Dec 31, 2022 | 640,000.00 |
| Sep 30, 2022 | 667,000.00 |
| Jun 30, 2022 | 216,000.00 |
| Mar 31, 2022 | 678,000.00 |
| Dec 31, 2021 | 653,000.00 |
| Sep 30, 2021 | 216,000.00 |